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Abstract
NPM1 mutations represent frequent genetic alterations in patients with acute myeloid leukemia (AML) associated with a
favorable prognosis. Different types of NPM1 mutations have been described. The purpose of our study was to evaluate the
relevance of different NPM1 mutation types with regard to clinical outcome. Our analyses were based on 349 NPM1-
mutated AML patients treated in the AMLCG99 trial. Complete remission rates, overall survival and relapse-free survival were
not significantly different between patients with NPM1 type A or rare type mutations. The NPM1 mutation type does not
seem to play a role in risk stratification of cytogenetically normal AML.
Citation: Pastore F, Greif PA, Schneider S, Ksienzyk B, Mellert G, et al. (2014) The NPM1 Mutation Type Has No Impact on Survival in Cytogenetically Normal
AML. PLoS ONE 9(10): e109759. doi:10.1371/journal.pone.0109759
Editor: Ralf Krahe, University of Texas MD Anderson Cancer Center, United States of America
Received April 26, 2014; Accepted September 6, 2014; Published October 9, 2014
Copyright:  2014 Pastore et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that, for approved reasons, some access restrictions apply to the data underlying the findings. The data cannot be made
available in a public repository due to ethical restrictions (case sensitive private patient data). The data can be made available upon request, and requests may be
sent to the corresponding author.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* Email: Friederike.Pastore@med.uni-muenchen.de
Introduction
The gene encoding nucleophosmin (NPM1), a nucleo-cytoplas-
matic shuttling protein with prominent nucleolar localization is
located on 5q35.1 and contains 12 exons. NPM1 is involved in
epigenetic control (binding of nucleic acids, centrosome duplica-
tion), ribosomal protein assembly as molecular chaperon and
regulation of the ARF-p53-tumor suppressor pathway [1,2].
NPM1 mutations can be found in 35% of patients with
cytogenetically normal acute myeloid leukemia (AML). They are
associated with a favorable prognosis in the absence of an
additional internal tandem duplication in the fms-related tyrosine
3 gene (FLT3-ITD), female gender, high white blood count
(WBC), high amount of bone marrow blasts as well as a high
platelet count [1].
In the vast majority of cases NPM1 mutations result in a
frameshift due to an insertion of four bases, which cluster in exon
12. Different types of NPM1 mutations have been described
according to the inserted tetranucleotide, the most common being
type A mutations (TCTG) in 80%, followed by type B (CATG)
and type D (CCTG) mutations in about 10%, and a spectrum of
other mutations accounting for 10% of cases. In rare cases,
insertions from 2 to 9 bases can occur (e.g. types E, F) [1].
The altered NPM1 protein (NPM1c+) contains an additional C
terminal nuclear export signal (NES) motif and loses at least one
tryptophan residue, causing an aberrant cytoplasmatic localization
of the protein [3].
Little is known about the prognostic relevance of the variable
NPM1 mutation types. In FLT3-ITD negative patients, a Korean
study found an adverse impact on overall survival (OS) and
duration of complete remission (CR) in NPM1 mutations other
than type A [4]. In FLT3-ITD positive patients, another recent
study reported an adverse OS in NPM1 type A mutations [5]
whereas - in contrast to Koh et al. - they did not observe an effect
of NPM1 mutation type in FLT3-ITD negative patients.
We aimed at studying the clinical relevance of NPM1 mutation
types on prognosis in a large homogeneously treated cohort of
cytogenetically normal AML patients.
Patients and Methods
Patients
Our analyses were based on a total of 783 patients with newly
diagnosed cytogenetically normal AML treated within the
randomized multicenter German AML Cooperative Group 99
(AMLCG99) trial comparing a double induction therapy with
thioguanine, cytarabine and daunorubicin (TAD) and high dose
mitoxantrone (HAM) versus HAM-HAM [6].
The AMLCG99 trial is registered at ClinicalTrials.gov
(NCT00266136) and was approved by the local institutional
review boards of all participating centers. Informed consent was
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obtained from all patients in accordance with the Declaration of
Helsinki.
Cytogenetic and molecular analyses
All cytogenetic and molecular analyses were performed on bone
marrow aspirates. Cytogenetic analyses were based on the
assessment of at least 20 metaphases and performed according
to the international system of cytogenetic nomenclature (ISCN)
guidelines [7]. Mutations of NPM1 [1], FLT3-ITD [8], the
FLT3-ITD mRNA level [9,10], CEBPA [11,12], were analyzed as
previously described. The nomenclature of the NPM1 mutation
type was performed according to the literature [1,13,14]. NPM1
mutations other than type A mutations were grouped together as
rare type mutations (NPM1-rare), NPM1 mutations other than
type A, B or D were grouped together as other mutations (NPM1-
other).
Outcome Parameters
OS was calculated from the date of randomization until death
from any cause. Surviving patients were censored at the date of
last follow-up. Relapse-free survival (RFS) was determined for
responders from the first day of CR until relapse or death from any
cause. Patients in CR that did not experience a relapse were
censored at the last disease assessment.
Figure 1. Overall Survival (OS) and Relapse-Free Survival (RFS) in 349 patients with cytogenetically normal acute myeloid leukemia
and NPM1 mutation treated in the AMLCG99 study. (A) OS in patients with NPM1 type A mutation versus NPM1 rare type mutation. (B) OS in
patients with NPM1 type A mutation versus NPM1 rare type mutation with or without an additional FLT3-ITD. (C) RFS in patients with NPM1 type A
mutation versus NPM1 rare type mutation. (D) RFS in patients with NPM1 type A mutation versus NPM1 rare type mutation with or without an
additional FLT3-ITD. Abbreviations: CR, complete remission; FLT3-ITD+, presence of an internal tandem duplication in the fms-related tyrosine 3
gene; FLT3-ITD-, absence of an internal tandem duplication in the fms-related tyrosine 3 gene; NPM1-A, mutation in the nucleophosmin gene
consisting of an insertion of the tetranucleotide TCTG; NPM1-RA, mutation in the nucleophosmin gene other than type A.
doi:10.1371/journal.pone.0109759.g001
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For patients who had undergone allogeneic transplantation
according to the study protocol, OS and RFS times were censored
at the time of transplantation.
Statistical Analysis
Continuous characteristics between patient groups were com-
pared using the Mann-Whitney U test for 2 groups and the
Kruskal-Wallis test for 3 groups. The x2-test for was applied for
categorical variables. Kaplan-Meier estimation for OS and RFS
was performed comparing NPM1-mutated patients with a type A
mutation (NPM1-A) versus NPM1-mutated patients with another
type of NPM1 mutation (rare type: NPM1-RA) as well as both
groups combined with either FLT3-ITD or without FLT3-ITD.
In a second analysis, patients with NPM1 mutations types A, B
and D were analyzed independently and compared to patients
carrying other mutations than A, B and D who were grouped
together as ‘‘NPM1- other’’.
Hazard ratios and 95% confidence intervals between the
different groups were estimated by Cox regression analyses.
Independent prognostic parameters for OS and RFS were
identified by univariable Cox regression analyses and a multivar-
iable Cox regression model using backward elimination with an
exclusion significance level of 5%. For all analyses, a p-value,0.05
was considered significant. For the estimation of the median




Analyses were performed in 349 NPM1-mutated patients of
667 patients with CN-AML treated within the AMLCG99 trial,
after exclusion of 106 patients without information of the NPM1
mutation status. For an overview of patient selection, please refer
to Figure S1 in File S1.
Out of 349 patients, 16% underwent allogeneic stem cell
transplantation in first CR. Median follow-up for OS was 45.3
months. Median OS was 45.6 months with 151 events. In 74% of
patients who achieved a CR, median RFS was 37.1 months with
115 events.
Patient characteristics are summarized in Table S1 in File S1.
The selected 677 patients from whom the 349 NPM1-mutated
patients were analyzed displayed similar patient characteristics and
outcome (OS and RFS, not significantly different) as the
unselected patients.
The majority of patients (77%) carried NPM1 type A
mutations, followed by 9% with NPM1 type D, 5% with
NPM1 type B mutations and 2% with NPM1 type I mutations.
All other mutations occurred in #1% of patients (Table S2 in
File S1).
NPM1 mutation type does not influence outcome
A) NPM1 mutation type A versus rare type
mutations. We did not observe any significant difference
between patients with NPM1 type A and rare mutations in
clinical or molecular parameters, in particular, there was no
difference regarding OS and RFS (Figures 1A and 1C, Table
S1 in File S1).
In patients with NPM1 mutation (NPM1+), the presence of an
FLT3-ITD (FLT3-ITD+) caused significant changes in WBC,
LDH level, amount of bone marrow blasts and a decrease in OS
and RFS compared to patients without FLT3-ITD (FLT3-ITD-)
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Figure 2. Overall Survival (OS) and Relapse-Free Survival (RFS) in 349 patients with cytogenetically normal acute myeloid leukemia
and NPM1 mutation treated in the AMLCG99 study. (A) OS in patients with NPM1 type A mutation versus NPM1 type B mutation versus NPM1
type D mutation versus NPM1 type other mutation. (B) RFS in patients with NPM1 type A mutation versus NPM1 type B mutation versus NPM1 type D
mutation versus NPM1 type other mutation. Abbreviations: CR, complete remission; FLT3-ITD+, presence of an internal tandem duplication in the
fms-related tyrosine 3 gene; FLT3-ITD-, absence of an internal tandem duplication in the fms-related tyrosine 3 gene; NPM1-A, mutation in the
nucleophosmin gene consisting of an insertion of the tetranucleotide TCTG; NPM1-B, mutation in the nucleophosmin gene consisting of an insertion
of the tetranucleotide CATG, NPM1-D, mutation in the nucleophosmin gene consisting of an insertion of the tetranucleotide CCTG, NPM1-other,
mutation in the nucleophosmin gene other than NPM1 mutation types A, B, D.
doi:10.1371/journal.pone.0109759.g002
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We did not observe any difference in patient characteristics, OS
or RFS between NPM1-A/FLT3-ITD- versus NPM1-RA/
FLT3-ITD- patients (Figure 1B and 1D, Table S1 in File
S1). Similar results were obtained for NPM1-A/FLT3-ITD+
versus NPM1-RA/FLT3-ITD+ patients, except for WBC which
was higher in the rare type group (p = 0.005).
In multivariable Cox regression analysis, parameters with
independent adverse impact on OS and RFS were older age, a
high WBC and the presence of an FLT3-ITD. Importantly, the
NPM1 mutation type (NPM1-A versus NPM1-RA) was not
significantly correlated with OS or RFS, neither in univariable,
(Table S3 in File S1) nor in multivariable Cox regression models
(Table 1).
Similar results were obtained for the effect of NPM1-A versus
NPM1-RA on OS and RFS in patients receiving chemotherapy
only (without allogeneic transplantation in first CR), patients with
de novo AML and patients ,60 or $60 years (text and Figures
S3, S4 and S5 in File S1).
B) NPM1 mutation types A versus B versus D versus other
mutations. We did not find a statistical difference with regard
to OS and RFS in patients with NPM1 type A, B, D and other
mutations (p = 0.937, p = 0.980) (Figures 2A and 2B). Further-
more, OS and RFS were similar between patients with type A, B,
D and other mutations without an additional FLT3-ITD (data not
shown). NPM1-A/FLT3-ITD+ patients showed similar OS and
RFS as patients with NPM1-B/FLT3-ITD+, NPM1-D/FLT3-
ITD+ and NPM1-other/FLT3-ITD+ patiens (data not shown). In
multivariable Cox regression analysis, older age, a high WBC and
presence of a FLT3-ITD were associated with an adverse
prognosis, whereas the type of NPM1 mutation (A versus B
versus D versus other) was not significantly associated with OS or
RFS (Table S4 in File S1). Similar results were obtained for
patients not receiving allogeneic transplantation (text in File S1).
Conclusions and Discussion
The aim of this study was to assess the relevance of different
NPM1 mutation types with regard to clinical and molecular
patient characteristics and outcome.
In the literature only few published studies have addressed this
topic revealing controversial results. Koh et al who investigated
only patients without an additional FLT3-ITD, found a negative
prognostic impact of rare type mutations on OS and duration of
CR [4]. Their analyses were based on 18 NPM1-mutated de novo
AML patients, 13 of which had a type A mutation versus 5 with a
rare type mutation. Thus, conclusions are limited due to small
sample size and, furthermore, patients were not treated homoge-
neously within a clinical trial.
In contrast, another study recently presented at the ASH
meeting involving 603 NPM1-mutated patients with intermediate
risk karyotype showed a trend towards a longer OS in rare type
versus type A NPM1 mutations [5]. In the presence of an FLT3-
ITD, type A patients had a worse OS compared to rare type
mutations, whereas there was no difference between these groups
in the absence of a FLT3-ITD.
Our study of a homogenous cohort with respect to treatment (all
patients are treated within one clinical trial) and cytogenetics (all
patients had a normal karyotype) did not reveal any difference in
molecular and clinical parameters including CR rates, OS and
RFS between type A and rare type NPM1 mutations. Even when
our patients were stratified according to FLT3-ITD status the type
of NPM1 mutation was not relevant for clinical outcome. This
was also true comparing NPM1 mutation types A, B, D versus
other. Moreover, the type of NPM1 mutation was not an
independent prognostic factor in a multivariable analysis.
Except for the addition of a NES causing an aberrant
cytoplasmatic localization of the mutated NPM1 protein, other
biochemical consequences of different NPM1 mutation types on a
protein level which might alter the binding of NPM1 targets have
not been fully explored and warrant further investigation.
In light of the low frequency and diversity of rare NPM1
mutations, however, it is very challenging to assess their individual
clinical relevance.
We conclude that the type of NPM1 mutation does not seem to
play a role in risk stratification of cytogenetically normal AML.
Supporting Information
File S1 Data supplement. Text, NPM1 mutation type does
not influence outcome - Subgroup analyses. A) NPM1 mutation
type A versus rare type mutationsin 292 patients receiving
chemotherapy only in 292 patients receiving chemotherapy only;
in 330 patients with de novo AML; in patients ,60 and $60 years
of age. B) NPM1 mutation types A versus B versus D versus other
mutations in 292 patients receiving chemotherapy only. Table S1,
Characteristics of NPM1-mutated patients and comparison
between those with type A and rare type with or without a
FLT3-ITD. Table S2, Frequency of different types of NPM1
mutations. Table S3, Univariable Cox regression for overall
survival (OS) and relapse-free survival (RFS). Table S4, Multivar-
iable Cox regression models for OS and RFS in 349 NPM1-
mutated patients. Figure S1, Overview of patient Selection. Figure
S2, Influence of a FLT3-ITD in 349 NPM1-mutated patients on
outcome. (A) OS in 349 NPM1-mutated patients. (B) RFS in
NPM1-mutated patients in CR. Figure S3, Overall Survival (OS)
and Relapse-Free Survival (RFS) in 292 patients with cytogenet-
ically normal acute myeloid leukemia and NPM1 mutation
treated in the AMLCG99 study, not receiving allogeneic
transplantation. (A) OS in patients with NPM1 type A mutation
versus NPM1 rare type mutation. (B) OS in patients with NPM1
type A mutation versus NPM1 rare type mutation with or without
an additional FLT3-ITD. (C) RFS in patients with NPM1 type A
mutation versus NPM1 rare type mutation. (D) RFS in patients
with NPM1 type A mutation versus NPM1 rare type mutation
with or without an additional FLT3-ITD. Figure S4, Overall
Survival (OS) and Relapse-Free Survival (RFS) in 330 patients
with de novo cytogenetically normal acute myeloid leukemia and
NPM1 mutation treated in the AMLCG99 study. (A) OS in
patients with NPM1 type A mutation versus NPM1 rare type
mutation. (B) OS in patients with NPM1 type A mutation versus
NPM1 rare type mutation with or without an additional FLT3-
ITD. (C) RFS in patients with NPM1 type A mutation versus
NPM1 rare type mutation. (D) RFS in patients with NPM1 type
A mutation versus NPM1 rare type mutation with or without an
additional FLT3-ITD. Figure S5, Overall Survival (OS) and
Relapse-Free Survival (RFS) in 197 patients ,60 years and 152
patients $60 years with cytogenetically normal acute myeloid
leukemia and NPM1 mutation treated in the AMLCG99 study.
(A) OS in patients ,60 years with NPM1 type A mutation versus
NPM1 rare type mutation. (B) OS in patients $60 years with
NPM1 type A mutation versus NPM1 rare type mutation. (C)
RFS in patients ,60 with NPM1 type A mutation versus NPM1
rare type mutation. (D) RFS in patients $60 with NPM1 type A
mutation versus NPM1 rare type mutation.
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